In summary, the present study demonstrated that a carbazole derivative ECCA significantly activates the p53 pathway to inhibit melanoma cell growth with little effect on primary melanocytes, providing potential for developing a new drug for a parallel therapeutic strategy with BRAF inhibitors to achieve maximal efficacy to efficiently treat melanoma in the clinic in the future. This evidence concerns the gene BRAF and melanoma.